

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2019-187

08 JUL 2019

TO:

THE GENERAL PUBLIC

SUBJECT:

Lifting the Advisory on the Registered Food Supplement NUWHITE PREMIUM Glutathione, Collagen & Vitamin E Food Supplement Capsule under FDA Advisories No. 2017-226 "Public Health Warning Against the Purchase and Consumption of the Following Unregistered Food Products and Food Supplements:" and 2017-245 "Public Health Warning Against the following Unregistered Food Supplements with their Corresponding Unapproved and Misleading Advertisements and Promotion"

The Food and Drug Administration (FDA) informs the public that the food supplement **NUWHITE PREMIUM Glutathione**, **Collagen & Vitamin E Food Supplement Capsule** has been registered by the Market Authorization Holder, **OXINA NUTRICOSMETICS CO.**, in accordance to existing FDA rules and regulations.



Figure 1. Approved label of NUWHITE PREMIUM Glutathione, Collagen & Vitamin E Food Supplement Capsule with registration number FR-4000002667665 valid until 23 January 2021

Accordingly, the list released in FDA Advisories No. 2017-226 and 2017-245 are hereby updated to remove the aforementioned food supplement.

The public is advised to always check if a food product is registered with the FDA. The FDA website (www.fda.gov.ph) has a Search feature which may be used by typing in the name of the product before purchasing. Kindly contact the FDA Center for Food Regulation and Research through e-mail at cfrr@fda.gov.ph, or call (02) 857-1900 loc. 8112 or 8105.

To report any sale or distribution of unregistered food products, the online reporting facility, **eReport** can be accessed at **www.fda.gov.ph/ereport**.

Civic Drive, Filinvest Corporate City, Alabang 1781 Muntinlupa, Philippines Trunk Line +63 2 857 1900 Fax +63 2 807 0751 Website: www.fda.gov.ph Email: info@fda.gov.ph



Management System ISO 9001:2015



The public health warning imposed on the remaining products listed in FDA Advisories No. 2017-226 and 2017-245 shall remain to be upheld and shall not be affected by the issuance of this advisory. Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.

ROLANDO ENRIQUE D. DOMINGO, MD, DPBO

Undersecretary of Health Officer-in-Charge, Director General

DTN 20190515124206